Intuitive Surgical, Inc., founded in 1995 and headquartered in Sunnyvale, California, is a trailblazer in the field of robotic-assisted surgery. The company is best known for developing and commercializing the da Vinci Surgical System, a groundbreaking robotic platform that enables surgeons to perform complex procedures with enhanced precision, vision, and control through minimally invasive techniques. Since receiving FDA approval in 2000, Intuitive has fundamentally reshaped the way surgeries are conducted across the globe, becoming synonymous with the evolution of digital surgery and surgical robotics.
The da Vinci system quickly became the standard in robotic surgery, setting the foundation for Intuitive’s rapid ascent in the healthcare technology sector. By leveraging cutting-edge engineering, advanced imaging, and data-driven insights, the company created a platform that not only improves surgical outcomes but also reduces patient recovery times and overall healthcare costs. Over the years, Intuitive has expanded its da Vinci product line to accommodate a wide range of surgical specialties including urology, gynecology, general surgery, thoracic surgery, and more, further solidifying its dominance in the operating room.
Intuitive Surgical operates with a razor-and-blade business model, wherein the sale of robotic systems is just the beginning of a long-term relationship with hospitals and surgical centers. Each installed system requires a continuous supply of proprietary instruments, accessories, and maintenance, creating a steady and high-margin recurring revenue stream. This model has allowed Intuitive to scale profitably while maintaining strong relationships with healthcare providers, and it has insulated the company from volatility associated with one-time hardware sales.
What sets Intuitive apart is not just its pioneering technology, but also its commitment to rigorous training, ongoing support, and surgeon enablement. The company has trained thousands of surgeons worldwide and developed an expansive network of educational programs and proctoring systems to ensure consistent clinical outcomes. With a deep focus on safety, usability, and continuous improvement, Intuitive has built a trusted brand that hospitals and surgical teams rely on for mission-critical procedures.
Over the past decade, Intuitive has continued to evolve by integrating artificial intelligence, data analytics, and advanced sensor technology into its systems. The launch of the da Vinci 5, its next-generation platform, marks a bold step forward. With exponential increases in computing power, force feedback, enhanced visualization, and software-ready infrastructure for future AI integration, the da Vinci 5 is positioned to lead the next chapter in surgical innovation. Intuitive’s commitment to innovation is further underscored by its investment in telesurgery, as demonstrated in its recent transatlantic demo connecting surgeons over 4,000 miles apart.
As of 2025, Intuitive has installed over 9,500 da Vinci systems worldwide and facilitated millions of procedures. With strong financial performance, no debt on its balance sheet, a growing portfolio of regulatory clearances, and an expanding global presence, Intuitive Surgical is not only a leader in robotic surgery—it is shaping the very future of how surgery will be done for decades to come.
A Razor-and-Blade Model Driving High-Margin Recurring Revenue
Intuitive Surgical’s financial engine is fueled by a recurring revenue model. Each da Vinci system sold becomes a perpetual revenue stream through instruments, accessories, and maintenance contracts. This razor-and-blade model means that even after an initial system installation, hospitals continue to generate revenue for Intuitive with every procedure performed. As of 2025, more than 80% of Intuitive’s revenue comes from recurring sources. This level of predictability, combined with minimal competition in its core markets, grants ISRG an enviable financial profile with gross margins exceeding 65% and operating margins consistently above 30%.
CHECK THIS OUT: Exact Sciences (EXAS) Just Made Cancer Detection 100x Easier! and Soleno Therapeutics (SLNO): The Biotech Company That Could Make You Rich.
Breakthrough Moment: 4,000-Mile Telesurgery Using da Vinci 5
At the Society of Robotic Surgery (SRS) conference in July 2025, Intuitive made headlines with a revolutionary telesurgery demonstration. Dr. Doug Stoddard in Peachtree Corners, Georgia, and Dr. Andrea Pakula in Strasbourg, France, were connected through a dual-console da Vinci 5 system across a transatlantic distance of more than 4,000 miles. Together, they performed a surgery on an advanced Intuitive-developed tissue model that mimicked live human tissue behavior.
The most groundbreaking aspect of this demo was the system’s ability to transmit force feedback across continents. This allowed both surgeons to feel tissue resistance in real time—transforming telesurgery from a distant concept into a near-future reality. The da Vinci 5’s telesurgery software is still in development and remains investigational, but this demo firmly positions Intuitive as a leader in the global digital surgery revolution.
A Legacy of Telesurgery and a Bold Vision for the Future
This wasn’t the first time Intuitive pushed boundaries in remote surgery. Back in 2001, the company helped make history with “Operation Lindbergh,” the world’s first transatlantic telesurgery performed between New York and Strasbourg. More than two decades later, Intuitive has now built the infrastructure and technological maturity to make such procedures reliable and repeatable. According to EVP and Chief Digital Officer Brian Miller, “Our focus is not on being first but on being rigorous in building the infrastructure to support safety, reliability, and consistent use.”
Intuitive CEO Dave Rosa echoed a similar sentiment, stating that telesurgery is part of a broader “telecollaboration suite” that includes telementoring, teleproctoring, and dual-console surgery—a strategy aimed at making minimally invasive care more accessible and affordable worldwide.
da Vinci 5: A Next-Gen Surgical Robot Designed for the Digital Age
The da Vinci 5 system is more than just an upgrade—it is a platform designed for the next generation of surgery. Featuring 10,000 times more computing power than its predecessor, da Vinci 5 is equipped with machine vision, force feedback, and redesigned instruments that unlock new dimensions of control and surgical insight. These advancements aim not only to make surgery safer but to create a data-rich environment that can train, guide, and inform future surgeons.
At the upcoming RoboBusiness 2025 conference in Santa Clara, Iman Jeddi, SVP and GM of Intuitive’s Multiport Platform, is set to deliver a keynote titled “Redefining the Future of Surgical Robotics.” His talk will provide a rare inside look at how da Vinci 5 was conceptualized, developed, and rolled out—highlighting how Intuitive balances innovation with safety, regulation, and patient outcomes.
Global Expansion and Regulatory Momentum
The company is also expanding its regulatory reach. Following FDA clearance in 2024, the da Vinci 5 recently earned CE Mark approval in Europe, allowing for commercial expansion across the continent. This global momentum was further amplified when Intuitive secured FDA clearance for new indications for its da Vinci Single Port (SP) system and received green light for its latest energy instruments designed to seal, cut, and dissect tissue—including a first-of-its-kind bipolar electrosurgical tool for lymphatic vessel transection.
These regulatory wins demonstrate not only the strength of Intuitive’s product pipeline but also its ability to execute in highly complex, compliance-heavy environments. With robotic surgery adoption still in its early stages globally—especially in emerging markets—the company is positioned to expand its total addressable market significantly over the next decade.
Financial Firepower and Consistent Outperformance
Intuitive’s Q2 2025 earnings report stunned Wall Street. Revenue grew over 17% year-over-year, while procedure volumes increased 18%, and adjusted EPS surged by 26% to $1.84. Analysts highlighted the robust growth in system placements, rising procedural adoption in both urology and general surgery, and higher instrument utilization across the installed base. Free cash flow remains strong, the balance sheet holds no debt, and Intuitive continues to pour capital into R&D and strategic expansion—all while returning value to shareholders through buybacks.
Despite its premium valuation, with a forward P/E near 70x, many analysts remain bullish. They argue that Intuitive’s growth trajectory, strong economic moat, and long-term secular tailwinds justify the price. Institutional interest has remained strong, with bullish options activity pointing toward continued upward momentum in the $500–$700 range.
A Market Poised for Robotic Domination
Robotic-assisted surgery is still in its early innings. Globally, less than 5% of applicable surgical procedures are performed robotically. As hospitals push for shorter recovery times, better outcomes, and minimally invasive procedures, demand for robotic solutions is expected to soar. Market research projects the robotic surgery market to grow from $3.3 billion in 2023 to as much as $18 billion by 2033. Intuitive’s early-mover advantage, surgical network, and data platform position it as the most likely winner in this transformation.
Final Thoughts: Why Intuitive Surgical is a Long-Term Winner
Intuitive Surgical is not just a medical device company—it’s a digital surgery platform transforming the future of medicine. With its newest da Vinci 5 system, it has demonstrated that it can adapt and lead even in a highly competitive, maturing industry. Its commitment to quality, patient safety, and future-focused innovation (such as telesurgery and machine vision) makes it one of the most compelling investments in the healthcare sector.
From a financial perspective, Intuitive boasts strong margins, explosive procedure growth, a fortress balance sheet, and a network effect that would take years—if not decades—for competitors to replicate. As hospitals around the world continue to adopt robotic surgery as the standard of care, Intuitive’s opportunity is still in the early stages.
For investors seeking exposure to high-quality healthcare innovation with real-world impact and a powerful track record, Intuitive Surgical remains a top-tier long-term buy.
READ ALSO: Johnson & Johnson (JNJ) can be the Next Trillion-Dollar Stock and Boston Scientific (BSX) Just Signed a $45M Deal—Here’s What It Means for Investors.
